Technology | April 17, 2015

Cerner and Qualcomm Collaborate on Home Health Monitoring Network

Qualcomm's 2net Platform will capture patient data from home, transmit it via Cerner's CareAware platform

Cerner, Qualcomm, home health monitoring, 2net, CareAware, EHR

April 17, 2015 — Cerner Corp. and Qualcomm Life Inc. announced an agreement to extend Cerner’s medical device connectivity capabilities beyond the hospital to the home. Cerner will leverage Qualcomm Life’s U.S. Food and Drug Administration (FDA)-listed 2net Platform and Hub to capture data from medical devices and sensors within a patient’s home, and transmit it to Cerner healthcare clients through Cerner’s CareAware device connectivity platform. Through this initiative, care providers can remotely monitor chronically ill patients in near-real time to enable proactive engagement to potentially reduce the risk of an acute care episode.

Qualcomm Life’s 2net Platform collects, stores and aggregates patient data from connected medical devices provided to the patient, such as weight scales, blood pressure monitors and pulse oximeters. These data values will transmit via CareAware to the Cerner Millennium electronic health record (EHR) and are viewable to the patient in HealtheLife, Cerner’s patient engagement solution. Extending CareAware to integrate devices within the home to the patient’s EHR will provide healthcare organizations a more comprehensive view in their efforts to focus on chronic condition management, reduce readmissions and improve patient health and satisfaction.

Qualcomm Life will join Cerner’s CareAware certification program, an initiative that creates alliances between Cerner and medical device manufacturers to better acquire data from devices to integrate with the EHR via CareAware device connectivity architecture.

Agnesian HealthCare is one of the first enterprise clients to implement the combined technologies to remotely monitor and manage at-risk patient populations. “It is increasingly important that providers are monitoring the whole health of an individual, not just at the point of care in the facility,” said Michael DeGeer, DPM, FACPS, FACFAS, vice president of population health management, Agnesian HealthCare. “Remote patient monitoring allows our clinicians to have access to patients’ health data, within the patient’s health record, while they are at home, which will provide the opportunity for clinicians to make informed interventions as needed.”

For more information: www.cerner.com, www.qualcommlife.com

Related Content

American Heart Association Introduces New Post-acute Care Heart Failure Certification
News | Heart Failure | July 03, 2019
The new Post-Acute Care Heart Failure Certification offered from the American Heart Association (AHA) provides...
Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
Overlay Init